All participants will be in a listen-only mode until the question-and-answer session of the conference. This call is being ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

Celebrities like Chrissy Teigen and Matthew Perry have been open about using ketamine for their mental health – here's what they've said ...

It has been used as a party drug for decades but is an "approved medical product as an injectable, short-acting anesthetic for use in humans and animals and as a nasal spray (Spravato) for ...

Spravato is classified as a Schedule III controlled substance and is only available through a restricted program called the Spravato REMS. The Food and Drug Administration (FDA) has approved ...

Credit: Johnson & Johnson. The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.

Now, the Food and Drug Administration (FDA) has expanded approval for Johnson & Johnson's nasal spray, Spravato, to be used as a standalone treatment for people with severe depression who haven't ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is difficult to treat. The United States Food and Drug Administration (FDA ...

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the FDA has blessed the nasal spray to be used as a monotherapy for major ...

Drug is the first and only approved monotherapy for refractory major depressive disorder. (HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...